38
Participants
Start Date
July 31, 2001
Primary Completion Date
October 31, 2006
Study Completion Date
May 31, 2007
Gemcitabine
The starting dose will be 1000mg/m2 IV, weekly x 7 with a one week rest followed by weekly x 3 with one week rest for the remainder of treatment.
Etanercept
Etanercept will be self administered subcutaneously by patients with injections 11 prepared by the investigational pharmacy, beginning 7 days prior to the first dose of gemcitabine and continued twice weekly for the duration of the study.
Ohio State University Medical Center, Columbus
Collaborators (1)
Immunex Corporation
INDUSTRY
Ohio State University Comprehensive Cancer Center
OTHER